Chimeric aquaretic and natriuretic polypeptides lacking vasodilatory activity

Patent metadata

Field	Value
Publication number	US-9102757-B2
Application number	US-201313943140-A
Country	US
Kind code	B2
Filing date	Jul 16, 2013
Priority date	Sep 8, 2006
Publication date	Aug 11, 2015
Grant date	Aug 11, 2015

Abstract

This document provides aquaretic and natriuretic polypeptides. For example, this document provides polypeptides having aquaretic and/or natriuretic activities. In some cases, a polypeptide provided herein can have aquaretic and natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing aquaretic and/or natriuretic activities within a mammal.

First claim

What is claimed is:

1. A natriuretic polypeptide less than 45 amino acid residues in length, wherein said polypeptide comprises, in an order from amino terminus to carboxy terminus:
(a) the sequence set forth in SEQ ID NO:2, and
(b) the sequence set forth in SEQ ID NO:3.

2. The polypeptide of claim 1 , wherein said polypeptide has natriuretic activity.

3. The polypeptide of claim 1 , wherein said polypeptide lacks vasodilatory activity.

4. The polypeptide of claim 1 , wherein said polypeptide lacks the sequence set forth in SEQ ID NO:1.

5. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:8.

6. The polypeptide of claim 1 , wherein said polypeptide consists of the sequence set forth in SEQ ID NO:8.

7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a natriuretic polypeptide less than 45 amino acid residues in length, wherein said polypeptide comprises, in an order from amino terminus to carboxy terminus:
(a) the sequence set forth in SEQ ID NO:2, and
(b) the sequence set forth in SEQ ID NO:3.

8. A method for increasing aquaretic and natriuretic activity within a mammal without lowering blood pressure, wherein said method comprises administering to said mammal a natriuretic polypeptide less than 45 amino acid residues in length, wherein said polypeptide comprises, in an order from amino terminus to carboxy terminus:
(a) the sequence set forth in SEQ ID NO:2, and
(b) the sequence set forth in SEQ ID NO:3.

9. The pharmaceutical composition of claim 7 , wherein said polypeptide has natriuretic activity.

10. The pharmaceutical composition of claim 7 , wherein said polypeptide lacks vasodilatory activity.

11. The pharmaceutical composition of claim 7 , wherein said polypeptide lacks the sequence set forth in SEQ ID NO:1.

12. The pharmaceutical composition of claim 7 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:8.

13. The pharmaceutical composition of claim 7 , wherein said polypeptide consists of the sequence set forth in SEQ ID NO:8.

14. The method of claim 8 , wherein said polypeptide lacks the sequence set forth in SEQ ID NO:1.

15. The method of claim 8 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:8.

16. The method of claim 8 , wherein said polypeptide consists of the sequence set forth in SEQ ID NO:8.

Assignees

• Mayo Foundation

Inventors

• Chen Horng H
• Burnett Jr John C

Classifications

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title